Press Releases

Year

August 4, 2022

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

SAN CARLOS, Calif. , Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the

July 25, 2022

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

SAN CARLOS, Calif. , July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L.

May 6, 2022

Allakos Provides Business Update and Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif. , May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the

March 1, 2022

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

REDWOOD CITY, Calif. , March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the

February 1, 2022

Allakos to Host Investor Day on February 15

– Management will discuss lirentelimab development and Allakos pipeline – REDWOOD CITY, Calif. , Feb. 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related

Investors

Press Releases

(Common Stock)

Investor Toolkit